Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.
10.1016/j.apsb.2016.07.006
- Author:
Wennan ZHAO
1
;
Yuling QIU
1
;
Dexin KONG
1
Author Information
1. Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences and Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
- Publication Type:Journal Article
- Keywords:
Anticancer;
Cancer therapy;
Drug candidate;
PI3K inhibitor;
PI3K/mTOR selectivity;
Phosphatidylinositol 3-kinase
- From:
Acta Pharmaceutica Sinica B
2017;7(1):27-37
- CountryChina
- Language:English
-
Abstract:
The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers. Class I PI3Ks are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH of the inositol ring to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt and the downstream effectors like mammalian target of rapamycin (mTOR) to play key roles in carcinogenesis. Therefore, PI3K has become an important anticancer drug target, and currently there is very high interest in the pharmaceutical development of PI3K inhibitors. Idelalisib has been approved in USA and Europe as the first-in-class PI3K inhibitor for cancer therapy. Dozens of other PI3K inhibitors including BKM120 and ZSTK474 are being evaluated in clinical trials. Multifaceted studies on these PI3K inhibitors are being performed, such as single and combinational efficacy, resistance, biomarkers, etc. This review provides an introduction to PI3K and summarizes key advances in the development of PI3K inhibitors.
